NASDAQ: FATE · Life Sciences · 4 alerts · CIK 1434316
Share price
$1.14Close, Nov 16
Market cap
$139M
Shares outstanding
121.57MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Fate Therapeutics Inc filings on SEC EDGAR ↗
Fate Therapeutics entered into a sales agreement with Leerink Partners to establish an at-the-market (ATM) offering program for up to $100 million of its common stock. The company is not obligated to sell any shares and will pay a commission of up to 3.0% on any gross proceeds. This program replaces a previous ATM facility that was terminated concurrently.
Fate Therapeutics reported third-quarter 2026 financial results, highlighting a cash position of $139.1 million and a runway extending into mid-2028. The company is advancing its RECLAIM-LN Phase 2 trial for FT819 in lupus nephritis and recently received a $15 million grant from the California Institute for Regenerative Medicine (CIRM) to support the program.
Term
Q3 2026
“The third quarter was defined by steady execution across our portfolio, bringing us closer to our goal of delivering off-the-shelf, master cell bank derived cell therapies to the patients who need them most.”
Bob Valamehr, Ph.D., MBA, President and Chief Executive Officer
“Our progress this year, together with continued extension of our cash runway, positions us well for important milestones ahead, and we remain focused on execution as we work to deliver across multiple fronts in 2027.”
Bob Valamehr, Ph.D., MBA, President and Chief Executive Officer
Fate Therapeutics CFO Kamal Adawi Sells $13.5K of Stock
Kamal Adawi, CFO, sold 6,582 shares of Fate Therapeutics Inc at $2.05 a share, worth $13.5K in total on Nov 3, 2026. Shares held after the trade: 93,418 (-6.6%).